JP2014524908A5 - - Google Patents

Download PDF

Info

Publication number
JP2014524908A5
JP2014524908A5 JP2014517015A JP2014517015A JP2014524908A5 JP 2014524908 A5 JP2014524908 A5 JP 2014524908A5 JP 2014517015 A JP2014517015 A JP 2014517015A JP 2014517015 A JP2014517015 A JP 2014517015A JP 2014524908 A5 JP2014524908 A5 JP 2014524908A5
Authority
JP
Japan
Prior art keywords
amino acid
peptide
seq
variant
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517015A
Other languages
English (en)
Japanese (ja)
Other versions
JP6184404B2 (ja
JP2014524908A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/042085 external-priority patent/WO2012177444A2/en
Publication of JP2014524908A publication Critical patent/JP2014524908A/ja
Publication of JP2014524908A5 publication Critical patent/JP2014524908A5/ja
Application granted granted Critical
Publication of JP6184404B2 publication Critical patent/JP6184404B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517015A 2011-06-22 2012-06-12 グルカゴン/glp−1レセプターコアゴニスト Expired - Fee Related JP6184404B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161500025P 2011-06-22 2011-06-22
US61/500,025 2011-06-22
PCT/US2012/042085 WO2012177444A2 (en) 2011-06-22 2012-06-12 Glucagon/glp-1 receptor co-agonists

Publications (3)

Publication Number Publication Date
JP2014524908A JP2014524908A (ja) 2014-09-25
JP2014524908A5 true JP2014524908A5 (show.php) 2015-07-30
JP6184404B2 JP6184404B2 (ja) 2017-08-23

Family

ID=47362407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517015A Expired - Fee Related JP6184404B2 (ja) 2011-06-22 2012-06-12 グルカゴン/glp−1レセプターコアゴニスト

Country Status (11)

Country Link
US (2) US9309301B2 (show.php)
EP (1) EP2723766A4 (show.php)
JP (1) JP6184404B2 (show.php)
KR (1) KR20140043793A (show.php)
CN (1) CN103748109A (show.php)
AU (1) AU2012273365A1 (show.php)
BR (1) BR112013032717A2 (show.php)
CA (1) CA2839867A1 (show.php)
MX (1) MX2013015168A (show.php)
RU (1) RU2014101697A (show.php)
WO (1) WO2012177444A2 (show.php)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100021480A1 (en) * 2005-10-27 2010-01-28 Peptron Co., Ltd Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same
PA8830501A1 (es) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
PE20181299A1 (es) 2011-06-10 2018-08-09 Hanmi Science Co Ltd Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
SMT201900078T1 (it) 2011-06-17 2019-02-28 Hanmi Science Co Ltd Un coniugato comprendente oxintomodulina e un frammento di immunoglobulina, e suo uso
JP6179864B2 (ja) 2011-06-22 2017-08-16 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン/glp−1レセプタコ−アゴニスト
CN104093735B (zh) 2011-09-23 2018-07-06 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
PT2864350T (pt) * 2012-06-21 2018-05-14 Hoffmann La Roche Análogos do glucagon que apresentam uma atividade sobre o recetor do gip
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013342321B2 (en) 2012-11-06 2017-09-28 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
CA2894765A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
EP3238734A1 (en) * 2013-03-14 2017-11-01 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
AR098614A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Compuesto para el tratamiento de hipoglicemia severa
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー/エス 医療用のglp−1/グルカゴン受容体コアゴニスト
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US10413593B2 (en) * 2014-10-24 2019-09-17 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and GLP-1 receptors
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
WO2016098275A1 (ja) * 2014-12-15 2016-06-23 日本電気株式会社 通信方法
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
UA121874C2 (uk) 2015-02-17 2020-08-10 Елі Ліллі Енд Компані Порошкова назальна композиція для лікування гіпоглікемії
KR20180015131A (ko) 2015-06-04 2018-02-12 안트리아바이오 인크. 부위-특이적 단백질 콘쥬게이트의 제조를 위한 아민 페길화 방법
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
AR104932A1 (es) 2015-06-22 2017-08-23 Lilly Co Eli Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
EP3359191A4 (en) 2015-10-05 2019-05-29 Merck Sharp & Dohme Corp. ANTIBODY PEPTIDE CONJUGATES WITH AGONISTEACTIVITY ON GLUCAGON RECEPTORS AND GLUCAGON-LIKE PEPTIDE-1
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
EP3377521A4 (en) 2015-10-27 2019-05-01 Merck Sharp & Dohme Corp. LONG-ACTING CO AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
US10493125B2 (en) 2015-12-09 2019-12-03 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and GLP-1 receptors
KR102508651B1 (ko) 2015-12-23 2023-03-13 더 존스 홉킨스 유니버시티 신경계 및 신경변성 상태의 요법으로서 장기간 작용하는 glf-1r 작용제
CN113546159B (zh) * 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
HUE059737T2 (hu) * 2015-12-31 2022-12-28 Hanmi Pharm Ind Co Ltd Glükagon, GLP-1 és GIP receptor aktiváló tripla aktivátor
WO2017192820A1 (en) * 2016-05-06 2017-11-09 Ionis Pharmaceuticals, Inc. Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
CN111132690A (zh) 2017-09-25 2020-05-08 默沙东公司 胰高血糖素和glp-1受体的长效共激动剂
WO2019092618A2 (en) * 2017-11-08 2019-05-16 Ionis Pharmaceuticals, Inc Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
WO2019140025A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
JP2022500465A (ja) * 2018-09-11 2022-01-04 アンビション ソチエタ レスポンサビリタ リミタータ ペプチドおよびその医学的使用
KR20210062650A (ko) * 2018-09-11 2021-05-31 앤비션 에스.알.엘. 펩티드 및 이의 의학적 용도
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
CN111349155B (zh) * 2018-12-24 2022-04-05 浙江和泽医药科技股份有限公司 一种胰高血糖素类似物及其制备方法和用途
TWI771669B (zh) * 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
CN111423506B (zh) * 2019-11-08 2023-06-27 成都奥达生物科技有限公司 一种glp-1化合物
EP3842061A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors
EP3842060A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
EP3842449A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors
AU2020431973A1 (en) * 2020-02-24 2022-09-22 Shenzhen Turier Biotech Co., Ltd. Polypeptide compound and application thereof in prevention or treatment of diabetes or diabetes complication
EP4183419A4 (en) * 2020-07-17 2025-04-02 Hanmi Pharm. Co., Ltd. THERAPEUTIC USE OF A COMBINATION WITH A LONG-ACTING TRIPLE AGONIST CONJUGATE OR TRIPLE AGONIST
AU2020483085B2 (en) 2020-12-23 2024-03-07 Zhejiang Doer Biologics Co., Ltd. Long-acting glucagon derivative
CN117120462A (zh) * 2021-01-22 2023-11-24 深圳市图微安创科技开发有限公司 多肽化合物在预防或治疗炎症性肠病及其相关的肠纤维化中的应用
JP7813887B2 (ja) 2021-12-02 2026-02-13 ケブンハウンス、ウニバーシテート 神経変性疾患の治療のためのペプチド薬物複合体
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物
US20240270821A1 (en) 2023-01-31 2024-08-15 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
CN121285571A (zh) 2023-06-09 2026-01-06 太阳医药工业有限公司 Glp-1/gip双重、glp-1/gcg双重和glp-1/gip/gcg三重受体激动剂
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275152A (en) 1977-02-03 1981-06-23 Eastman Kodak Company Hydrolysis of protein-bound cholesterol esters
PT83613B (en) 1985-10-28 1988-11-21 Lilly Co Eli Process for the selective chemical removal of a protein amino-terminal residue
NZ232562A (en) 1989-02-17 1992-10-28 Coselco Mimotopes Pty Ltd Immobilised peptide - solid support comprising a cleavable ester link between the peptide carboxy terminus and the solid support
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
JP3262329B2 (ja) 1990-01-24 2002-03-04 アイ. バックレイ,ダグラス 糖尿病治療に有用なglp―1アナログ
CA2024855C (en) 1990-09-07 1997-12-09 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Process and intermediates for producing glucagon
JPH04145099A (ja) 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Gip様活性を有するポリペプチド誘導体及びその用途
US5510459A (en) 1991-01-17 1996-04-23 Zymogenetics, Inc. Glucagon antagonists
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5480867A (en) 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
EP0879279A4 (en) 1996-02-06 2000-07-12 Lilly Co Eli DIABETE TREATMENT
JP2000516912A (ja) 1996-06-05 2000-12-19 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング エキセンジン類似体、それらの製造方法およびそれらを含有する製剤
CA2265454A1 (en) 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998024464A1 (en) 1996-12-03 1998-06-11 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
DE69926007T2 (de) 1998-10-07 2005-12-29 Medical College Of Georgia Research Institute, Inc. Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
US6903186B1 (en) 1998-12-07 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S Analogues of GLP-1
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
US6921748B1 (en) 1999-03-29 2005-07-26 Uutech Limited Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
EP1356295A2 (en) 2000-04-27 2003-10-29 Bionebraska, Inc. Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucos
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
CA2410604A1 (en) 2000-06-14 2001-12-20 Cytovax Biotechnologies, Inc. Use of coiled-coil structural scaffold to generate structure-specific peptides
ES2321439T3 (es) 2000-06-16 2009-06-05 ELI LILLY & COMPANY Analogos del peptido-1 similar a glucagon.
SE525948C2 (sv) 2000-06-28 2005-05-31 Modig Technical Consulting Ab Fleroperationsmaskin
CA2417100A1 (en) 2000-08-02 2002-02-07 Theratechnologies Inc. Modified peptides with increased potency
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US20020045572A1 (en) 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
WO2002026265A2 (en) 2000-09-29 2002-04-04 Schering Corporation Pegylated interleukin-10
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
EP1572885A2 (en) 2001-08-08 2005-09-14 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
CA2452044A1 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
AU2002348469B2 (en) 2001-10-18 2008-03-13 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
CA2463803A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US7482321B2 (en) 2002-01-08 2009-01-27 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
EP1575490A4 (en) 2002-06-04 2007-08-08 Lilly Co Eli MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1)
WO2003103697A2 (en) 2002-06-11 2003-12-18 Cell Therapeutics Scandinavia Ab Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
CA2489323A1 (en) 2002-06-15 2003-12-24 Enteromed, Inc. Treatment of non-alcoholic fatty liver disease
CA2497794A1 (en) 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
WO2004078777A2 (en) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
HRP20050683A2 (en) 2003-03-19 2006-07-31 Eli Lilly And Company Polyethylene glycol linked glp-1 compounds
PT1620118E (pt) 2003-04-08 2014-10-16 Yeda Res & Dev Fármacos peguilados de modo reversível
AU2004240630B2 (en) 2003-05-15 2010-10-07 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
WO2004105781A2 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
BRPI0411132B8 (pt) 2003-06-12 2021-05-25 Lilly Co Eli protéina de fusão heteróloga e seus usos
US20050124550A1 (en) 2003-06-18 2005-06-09 Peri Krishna G. Compounds that modulate the glucagon response and uses thereof
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
US7364875B2 (en) 2003-10-30 2008-04-29 Cresent Innovations, Inc. Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
BRPI0417717A (pt) 2003-12-18 2007-04-03 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20080318837A1 (en) 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US8404637B2 (en) 2005-02-11 2013-03-26 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP1863537A2 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
WO2006121904A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
PL1881850T3 (pl) 2005-05-13 2011-03-31 Lilly Co Eli Pegylowane związki GLP-1
RU2485135C2 (ru) 2005-06-13 2013-06-20 Импиэриэл Инноувейшнс Лимитид Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
WO2007028633A2 (en) 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
EP1937716A2 (en) 2005-09-08 2008-07-02 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
CN101534846B (zh) 2005-11-07 2014-11-05 印第安纳大学研究及科技有限公司 显示生理学溶解性和稳定性的胰高血糖素类似物
US7928058B2 (en) 2006-02-22 2011-04-19 Merck Sharp & Dohme Corp. Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
US20090054305A1 (en) 2006-03-15 2009-02-26 Novo Nordisk A/S Mixtures of Amylin and Insulin
CN101432025B (zh) 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
EP2007804B1 (en) 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
WO2008022015A2 (en) 2006-08-11 2008-02-21 Trustees Of Tufts College Retro-inverso incretin analogues, and methods of use thereof
AU2007284365A1 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
EP2615108B1 (en) 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
WO2008076933A2 (en) 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
CN101578102B (zh) 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US7994122B2 (en) 2007-06-15 2011-08-09 Zealand Pharma A/S Glucagon analogues
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
EP2650006A1 (en) 2007-09-07 2013-10-16 Ipsen Pharma S.A.S. Analogues of exendin-4 and exendin-3
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
WO2009034117A1 (en) 2007-09-11 2009-03-19 Novo Nordisk A/S Mixture comprising an amylin peptide and a protracted insulin
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
AU2008318876B2 (en) 2007-10-30 2014-05-15 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and GLP-1 agonist activity
AU2008318986B2 (en) 2007-10-30 2014-12-04 Indiana University Research And Technology Corporation Glucagon antagonists
WO2009059278A1 (en) 2007-11-02 2009-05-07 Centocor, Inc. Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
ES2733355T3 (es) 2008-02-01 2019-11-28 Ascendis Pharma As Profármaco que comprende un enlazador autoescindible
CL2009001425A1 (es) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal.
PA8830501A1 (es) * 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
CN102088989B (zh) 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
JP2012512898A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション ジペプチド結合薬用剤
EP2376097A4 (en) * 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
RU2604067C2 (ru) 2010-05-13 2016-12-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers

Similar Documents

Publication Publication Date Title
JP2014524908A5 (show.php)
JP2014525901A5 (show.php)
HRP20170890T1 (hr) Suagonisti glukagonskog/glp-1 receptora
RU2014101697A (ru) Коагонисты рецепторов глюкагона/glp-1
JP2018515088A5 (show.php)
ES2351661T3 (es) Péptido-2 análogo al glucagón.
JP2013518115A5 (show.php)
CN104945500B (zh) 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
JP2011524420A5 (show.php)
JP6121330B2 (ja) 作用持続時間が増した改変ポリペプチド
FI3368555T3 (fi) Kaksitoimisia proteiineja ja niitä sisältävä farmaseuttinen koostumus
JP2014507402A5 (show.php)
HRP20200503T1 (hr) Fuzijski proteini
CN109810198B (zh) 利用免疫球蛋白片段的位点特异性glp-2缀合物
JP2016512213A5 (show.php)
JP2010515686A5 (show.php)
JP2013533849A5 (show.php)
HRP20140616T1 (hr) Peptidni analog oksintomodulina
JP2016521257A5 (show.php)
JP2012530145A5 (show.php)
KR20140058104A (ko) 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
CA2797089A1 (en) Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
HRP20201353T1 (hr) Agonisti glukagonskog receptora
JP2016511752A5 (show.php)
RU2015101697A (ru) Аналоги глюкагона, обладающие активностью рецептора gip